Olaparib plus abiraterone for mCRPC: are biomarkers necessary?
Gerhardt Attard, MD, PhD, FRCP, of the The Royal Marsden NHS Foundation Trust, London, UK, speaks from the UK Oncology Forum (OF) 2018, held in Liverpool, UK, on the topic of metastatic castration-res... Author: VJOncology Added: 06/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2018 Category: Cancer & Oncology Source Type: podcasts

MSI as a biomarker in gynecological cancer
Microsatellite instability (MSI) in tumors is a known predictor of response to certain therapies in gynecological cancer. In this video, Alexandra Leary, MD, PhD, of the Gustave Roussy Institute of On... Author: VJOncology Added: 06/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Launching Phase 2 Trial In Multi-Center Fashion | Currently Evaluated in Bone Marrow Transplantation
Aman Chauhan, MBBS, University of Kentucky shares Launching Phase 2 Trial In Multi-Center Fashion | Currently Evaluated in Bone Marrow Transplantation at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Anti-VEGF Therapy Has Been Standard | Field is Changing Dramatically
Brian I. Rini, MD, Cleveland Clinic explains Anti-VEGF Therapy Has Been Standard | Field is Changing Dramatically at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Telotristat for Carcinoid Syndrome Diarrhea | Wish for More Trials, Products, Pipeline Drugs
Aman Chauhan, MBBS, University of Kentucky shares Telotristat for Carcinoid Syndrome Diarrhea | Wish for More Trials, Products, Pipeline Drugs at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Add Amino Modulators to Increase Efficacy | Starting to Get Complete Response Rates
Brian I. Rini, MD, Cleveland Clinic explains Adding Amino Modulators to Increase Efficacy | Starting to Get Complete Response Rates at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Data Showed Diarrhea From Chemotherapy | Data Showed Diarrhea From Chemotherapy
Aman Chauhan, MBBS, University of Kentucky shares Data Showed Diarrhea From Chemotherapy at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Combinations Being Developed for Kidney Cancer | Efficacy Will Drive Treatment Choices
Brian I. Rini, MD, Cleveland Clinic explains Combinations Being Developed for Kidney Cancer | Efficacy Will Drive Treatment Choices at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

enterade is a Medical Food | Does Not Need Formal Prescription. OTC
Aman Chauhan, MBBS, University of Kentucky explains enterade is a Medical Food | Does Not Need Formal Prescription. OTC at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Patient Reported Outcomes Measure Tolerabilty | Trial Showed Benefits for Regimen Over Sunitinib
Brian I. Rini, MD, Cleveland Clinic shares Patient Reported Outcomes Measure Tolerabilty | Trial Showed Benefits for Regimen Over Sunitinib at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

enterade Amino Acid Based Rehydration Solution | 70% of Patients Had Benefit in Diarrhea Reduction
Aman Chauhan, MBBS, University of Kentucky explains enterade Amino Acid Based Rehydration Solution | 70% of Patients Had Benefit in Diarrhea Reduction at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

PR Results IMmotion151 Study | Progression-Free Survival & Encouraging Signals
Brian I. Rini, MD, Cleveland Clinic explains PR Results IMmotion151 Study | Progression-Free Survival & Encouraging Signals at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Is Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 & lt;1%, & amp; High TMB? New Data from CheckMate 227 (BMIC-040)
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in p... Author: BeaconMedIC Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Target Tumors More Effectively | Better Combinations, Find Mechanisms of Resistance
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Target Tumors More Effectively | Better Combinations, Find Mechanisms of Resistance at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Focus on Potentially Predictive Markers | NLR Blood Test May Help Prognosticate Patients
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Focus on Potentially Predictive Markers | Neutrophil-to-Lymphocyte Ratio Blood Test May Help Prognosticate Patients at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

ASCO Helps Impact Ability to Communicate | Helps Understand Knowledge Gaps
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares ASCO Helps Impact Ability to Communicate | Helps Understand Knowledge Gaps at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

CaM6 In Collaboration w German Cancer Ctr. | ILDR2 In Collaboration w Compugen Ltd.
Scott Z. Fields, MD, Bayer Pharmaceuticals explains CaM6 In Collaboration w German Cancer Ctr. | ILDR2 In Collaboration w Compugen Ltd. at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Moving Toward Precision Medicine | Field is Growing Quickly & Changes are Coming
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Moving Toward Precision Medicine | Field is Growing Quickly & Changes are Coming at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Thorium Platform Based on Initial Radium (Xofigo) | Thorium Delivers Alpha Radiation
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Thorium Platform Based on Initial Radium (Xofigo) | Thorium Delivers Alpha Radiation at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Bladder Cancer is No Longer Just One Disease | Different Biologies & Response in Benefit
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Bladder Cancer is No Longer Just One Disease | Different Biologies & Response in Benefit at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2
Scott Z. Fields, MD, Bayer Pharmaceuticals explains PI3-K Initially Developed in Follicular Lymphoma | Regorafenib Showed Benefit in Randomized Phase 2 at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Erdafitinib Currently Not FDA-Approved | Granted Breakthrough Designation Therapy
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Erdafitinib Currently Not FDA-Approved | Granted Breakthrough Designation Therapy at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

DHODH Inhibitor Pyrimidine Synthesis & #124; FGFR Inhibitor has Response Rate of 24%
Scott Z. Fields, MD, Bayer Pharmaceuticals explains DHODH Inhibitor Pyrimidine Synthesis | FGFR Inhibitor has Response Rate of 24% at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Studies for Fibroblast Growth Factors Receptors | Mutations & Trans-Location Fusion Protiens
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Studies for Fibroblast Growth Factors Receptors | Mutations & Trans-Location Fusion Proteins at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor
Scott Z. Fields, MD, Bayer Pharmaceuticals explains Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Therapy for Metastatic Urothelial Carcinoma | Erdafitnib, a Pan-FGFR Inhibitor
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Therapy for Metastatic Urothelial Carcinoma | Erdafitnib, a Pan-FGFR Inhibitor at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy in gynecological cancers: current and future landscape
Immunotherapy treatment within oncology is a field showing great promise. Here, Alexandra Leary, MD, PhD, of the Gustave Roussy Institute of Oncology, Paris, France, explores the plausibility of using... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Management of immunotherapy toxicity in gynecological cancers
Physicians who are dealing with gynecological tumors have a limited experience of how to deal with the complications and toxicity associated with immunotherapy, suggests Alexandra Leary, MD, PhD, of t... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Is the oral care of cancer patients being neglected?
Sonja Hoy, BS, PGDip, of The Royal Marsden NHS Foundation Trust, London, UK, discusses the importance of good oral hygiene in cancer patients at the UK Oncology Forum (OF) 2018, held in Liverpool, UK.... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

How to manage and care for cancer patients in an ever-changing world of treatments
How to maintain optimal patient safety and wellbeing is a constant concern and priority for healthcare professionals. At the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Verna Lavender, PhD, P... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

New radiotherapy combinations
Gerry Hanna, MD, from Queens University Belfast, Belfast, UK, provides an insight into the two new landmark platforms investigating radiotherapy-drug combinations for non-small lung cancer (NSCLC). T... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

MRI and MR-LINAC guided radiotherapy
CT scans are currently the standard for mapping targeted areas for cancer treatment; however, MRI has been shown to produce much better soft tissue definition. This advantage is discussed by David Seb... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

MRI and MR-LINAC guided radiotherapy
CT scans are currently the standard for mapping targeted areas for cancer treatment; however, MRI has been shown to produce much better soft tissue definition. This advantage is discussed by David Seb... Author: VJHemOnc Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Identifying TP53 disruptions: a diagnostic measure in CLL
Current diagnostic techniques for chronic lymphocytic leukemia (CLL), which include Sanger sequencing and fluorescent in-situ hybridization, can be complex and costly. Here, Anna Schuh, MD, PhD, MRCP,... Author: VJHemOnc Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Predictors of outcome for follicular lymphoma
The Genomics England program could play a key role in personalizing the treatment of patients with follicular lymphoma, through helping identify predictors of treatment outcome. Speaking at British So... Author: VJHemOnc Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Alex Lyon, Interview, BSH 2018, General, Treatment, cardiotoxicity, cardiac dysfunction, chemotherapy, disease risk, clinical trials, research, personalized medicine, cardio-oncology, cardiology, side effects, toxicity, cardioprotection, heart diseas
The field of cardio-oncology is growing on both a national and international scale. In this interview, Alex Lyon, MA, BM BCh, PhD, FRCP, from Imperial College, London, UK, talks about the formation of... Author: VJHemOnc Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Alex Lyon, Interview, BSH 2018, Treatment, General, Cancer, therapy, prevention, cardiovascular complications, heart failure, chemotherapy, adverse events, cardio-oncology, cardiology, side effects, toxicity
Due to the success of current treatments, patients are living longer and surviving cancer. However, certain treatments can cause cardiac complications which have a significant impact on the individual... Author: VJHemOnc Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Cardio-oncology: a new medical field
With the increasing life expectancy of cancer patients, the long-term consequences of cancer therapy are becoming an increasing issue. Anthracycline-induced heart failure is a classic example of an ad... Author: VJHemOnc Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Discontinuing treatment and predicting relapse in CML
Chronic myeloid leukemia (CML) stem cells are thought to evade treatment through disruption in the environment within the bone marrow, creating a proinflammatory microenvironment in which there is exc... Author: VJHemOnc Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Combination and monotherapies in NSCLC
An influx of novel therapies into the field of non-small cell lung cancer (NSCLC) has allowed healthcare professionals to utilize both combination and monotherapies in clinical practice. Speaking at t... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Guiding NSCLC treatment with biomarkers
The implementation of biomarkers into clinical practice is an exciting area of research, and the field of non-small cell lung cancer (NSCLC) is no exception to this. In this interview, Alastair Greyst... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Progress in novel NSCLC therapies in the UK
The management of patients with metastatic non-small cell lung cancer (NSCLC) is a field which has seen drastic improvement in the past few years. Here, Alastair Greystoke, PhD, of the University of N... Author: VJOncology Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Find Better Predictive Biomarkers for Response | Expand Data to Other of T-Cell Malignancies
Pierluigi Porcu, MD, Thomas Jefferson University, shares Find Better Predictive Biomarkers for Response | Expand Data to Other of T-Cell Malignancies at ASCO 2018 Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Clear Data for Nivolumab & Ipilimumab | In the Frontline for Intermediate & Poor-Risk Patients
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Clear Data for Nivolumab & Ipilimumab | In the Frontline for Intermediate & Poor-Risk Patients at ASCO 2018 Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Huge Need for Better Therapy for CTCL | Hope for FDA-Approval of Drug Based on Data
Pierluigi Porcu, MD, Thomas Jefferson University talks about a Huge Need for Better Therapy for CTCL | Hope for FDA-Approval of Drug Based on Data Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

New Combination Strategy for Metastatic RCC | Checkmate-214 Data for Nivolumab & Ipilimumab
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains New Combination Strategy for Metastatic RCC | Checkmate-214 Data for Nivolumab & Ipilimumab at ASCO 2018 Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Compliance of MAVERICK Dataset was 95%-96%| Analysis Based on Longitudinal Assessment
Pierluigi Porcu, MD, Thomas Jefferson University explains Compliance of MAVERICK Dataset was 95%-96%| Analysis Based on Longitudinal Assessment at ASCO 2018 Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Poor-Risk Patients Enrolled in Study for Surgery | Surgery is Not Significantly Better than Treatment
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, Poor-Risk Patients Enrolled in Study for Surgery | Surgery is Not Significantly Better than Treatment at ASCO 2018 Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Efficacy Moga, Room for Improvement | In Terms of Response Rate & Progression-free Survival
Pierluigi Porcu, MD, Thomas Jefferson University explains Efficacy Moga, Room for Improvement | In Terms of Response Rate & Progression-free Survival Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2018 Category: Cancer & Oncology Source Type: podcasts